




RealRate

PHARMACEUTICAL 2018

Larimar Therapeutics Inc.
Rank 180 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2018

Larimar Therapeutics Inc. Rank 180 of 349

The relative strengths and weaknesses of Larimar Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Larimar Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 257% points. The greatest weakness of Larimar Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 125% points.

The company's Economic Capital Ratio, given in the ranking table, is -188%, being 89% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	104,925
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,293
Liabilities, Non-Current	0
Other Assets	57
Other Compr. Net Income	22
Other Expenses	0
Other Liabilities	20,000
Other Net Income	971
Property and Equipment	528
Research and Development	40,839
Revenues	0
Selling, General and Administrative Expense	12,160

Output Variable	Value in 1000 USD
Assets	105,510
Liabilities	27,293
Expenses	52,999
Stockholders Equity	78,217
Net Income	-52,028
Comprehensive Net Income	-52,017
Economic Capital Ratio	-188%

